Education
About Us
Working with TipRanks
Follow Us
Virax Biolabs Group Ltd. Class A (VRAX)
:VRAX
RESEARCH TOOLSreports
Total Valuation
Virax Biolabs Group Ltd. Class A has a market cap or net worth of ―. The enterprise value is -$74.44K.
Market Cap―
Enterprise Value-$74.44K
Share Statistics
Virax Biolabs Group Ltd. Class A has 4,341,956 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,341,956
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Virax Biolabs Group Ltd. Class A’s return on equity (ROE) is -1.06 and return on invested capital (ROIC) is -103.22%.
Return on Equity (ROE)-1.06
Return on Assets (ROA)-0.94
Return on Invested Capital (ROIC)-103.22%
Return on Capital Employed (ROCE)-1.07
Revenue Per Employee372.41
Profits Per Employee-356.90K
Employee Count17
Asset Turnover<0.01
Inventory Turnover0.63
Valuation Ratios
The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio―
PS Ratio0.00
PB Ratio0.48
Price to Fair Value0.00
Price to FCF-0.71
Price to Operating Cash Flow-0.59
PEG Ratio-0.02
Income Statement
In the last 12 months, Virax Biolabs Group Ltd. Class A had revenue of 6.33K and earned -6.06M in profits. Earnings per share was -1.96.
Revenue6.33K
Gross Profit-53.07K
Operating Income-6.16M
Pretax Income-6.20M
Net Income-6.06M
EBITDA-5.80M
Earnings Per Share (EPS)-1.96
Cash Flow
In the last 12 months, operating cash flow was -4.71M and capital expenditures -707.92K, giving a free cash flow of -5.42M billion.
Operating Cash Flow-4.71M
Free Cash Flow-5.42M
Free Cash Flow per Share-1.25
Dividends & Yields
Virax Biolabs Group Ltd. Class A pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.29
52-Week Price Change-12.82%
50-Day Moving Average0.94
200-Day Moving Average1.50
Relative Strength Index (RSI)59.49
Average Volume (3m)89.25K
Important Dates
Virax Biolabs Group Ltd. Class A upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Virax Biolabs Group Ltd. Class A as a current ratio of 7.27, with Debt / Equity ratio of 6.62%
Current Ratio7.27
Quick Ratio7.13
Debt to Market Cap0.00
Net Debt to EBITDA0.66
Interest Coverage Ratio-105.93
Taxes
In the past 12 months, Virax Biolabs Group Ltd. Class A has paid -136.66K in taxes.
Income Tax-136.66K
Effective Tax Rate0.02
Enterprise Valuation
Virax Biolabs Group Ltd. Class A EV to EBITDA ratio is 0.66, with an EV/FCF ratio of 0.75.
EV to Sales-608.43
EV to EBITDA0.66
EV to Free Cash Flow0.75
EV to Operating Cash Flow0.84
Balance Sheet
Virax Biolabs Group Ltd. Class A has $7.38M in cash and marketable securities with $603.20K in debt, giving a net cash position of -$6.78M billion.
Cash & Marketable Securities$7.38M
Total Debt$603.20K
Net Cash-$6.78M
Net Cash Per Share-$1.56
Tangible Book Value Per Share$0.00
Margins
Gross margin is 39.59%, with operating margin of -97344.76%, and net profit margin of -95739.17%.
Gross Margin39.59%
Operating Margin-97344.76%
Pretax Margin-97992.31%
Net Profit Margin-95739.17%
EBITDA Margin-91649.46%
EBIT Margin-97073.35%
Analyst Forecast
The average price target for Virax Biolabs Group Ltd. Class A is $3.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$3.00
Price Target Upside194.12% Upside
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―